Orciprenaline

Orciprenaline
Clinical data
Synonyms Metaproterenol (USAN US)
AHFS/Drugs.com monograph
MedlinePlus a682084
Pregnancy
category
  • AU: A
  • US: C (Risk not ruled out)
    Routes of
    administration
    Inhalation (MDI) and tablets
    ATC code
    Legal status
    Legal status
    Pharmacokinetic data
    Bioavailability 3% if inhaled, 40% if taken orally
    Metabolism Gastrointestinal and hepatic
    Elimination half-life 6 hours
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    ECHA InfoCard 100.008.701 Edit this at Wikidata
    Chemical and physical data
    Formula C11H17NO3
    Molar mass 211.258 g/mol
    3D model (JSmol)
    Chirality Racemic mixture
    Solubility in water 9.7 mg/mL (20 °C)
     ☒N☑Y (what is this?)  (verify)

    Orciprenaline, also known as metaproterenol, is a bronchodilator used in the treatment of asthma.[1][2] Orciprenaline is a moderately selective β2 adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on α adrenergic receptors. The pharmacologic effects of β adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through β adrenergic receptors of intracellular adenylyl cyclase, the enzyme which catalyzes the conversion of ATP to cAMP. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.

    Possible side effects

    • tremor
    • nervousness
    • dizziness
    • weakness
    • headache
    • nausea
    • tachycardia
    Rare side effects that could be life-threatening
    • increased difficulty breathing
    • rapid or increased heart rate
    • irregular heartbeat
    • chest pain or discomfort

    Brand names

    • Alupent
    • Metaprel
    • Orcibest

    References

    1. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). "DrugBank 3.0: a comprehensive resource for omics research on drugs". Nucleic Acids Res. 39 (Database issue): D1035–41. doi:10.1093/nar/gkq1126. PMC 3013709. PMID 21059682.
    2. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008). "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic Acids Res. 36 (Database issue): D901–6. doi:10.1093/nar/gkm958. PMC 2238889. PMID 18048412.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.